ROCKET PHARMACEUTICALS, INC. (RCKT)
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
Address
350 FIFTH AVENUE
NEW YORK, NY 10118
Founded
1999
Number of Employees
268
Website
http://www.rocketpharma.com
Buyback
Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
---|---|---|---|---|---|---|---|---|---|---|---|---|
$ Amount Purchased ($ in 000s) |
- | - | - | - | $1,393 | - | - | - | - | - | - | $1,393 |
Average Price | - | - | - | - | $13.93 | - | - | - | - | - | - | $13.93 |
# Shares Purchased | - | - | - | - | 100,000 | - | - | - | - | - | - | 100,000 |
Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Return to Date | - | - | - | - | 36.4% | - | - | - | - | - | - | 36.4% |
S&P 500 Return to Date | - | - | - | - | 104.9% | - | - | - | - | - | - | 104.9% |
Excess Total Return | - | - | - | - | -68.5% | - | - | - | - | - | - | -68.5% |
Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
Percentile Rank | - | - | - | - | 53% | - | - | - | - | - | - | 65% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)